Even though BTKis have shown modest therapeutic activity in DLBCL (i.e., ORR of 23% for ibrutinib in relapsed patients, of 24% for acalabrutinib in DLBCL patients regardless of their molecular subtype, and of 36% for zanubrutinib in ABC DLBCL patients), Yang et al.[93] performed retrospective biomarker assessments and showed that zanubrutinib could have antitumor activity in patients with mutations in Cluster of Differentiation 79-B (CD79B) and Myeloid Differentiation primary response 88 (MYD88). This evidence concerns the gene MYD88 and diffuse large B-cell lymphoma.